Lilly, Eisai and Biogen seek more specifics in FDA guidance on early Alzheimer’s disease
Alzheimer’s drug manufacturers are asking the FDA to give them more clarity on the different stages of the disease in comments they’ve submitted on the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
